Transparency Market Research Report Added “Transfection Technology Market” to its database.
Global Transfection Technology Market: Overview
Transfection is a process that involves production of genetically modified cells with the delivery of foreign nucleic acid (DNA or RNA) into the cell. There are two types of transfection technologies that include stable and transient. While stable transfection is permanent and the genes are continually expressed even after the host cell replicates, transient transfected genes are expressed for a limited period of time and are not integrated into the host genome. Increasing prevalence of cancer and growing obese population drives the global transfection technology market. In addition, initiatives taken by various government organizations also further accentuates the growth of this market. The global transfection technology market was valued at USD 386.4 million in 2012 and is expected to grow at a CAGR of 9.7% from 2013 to 2019, to reach an estimated value of USD 768.2 million by 2019.
Transfection technologymarket is segmented mainly by types of method and application. The method segment of the market is classified as reagent-based method, instrument-based method and virus-based method. The reagent-based method is further segmented as lipid mediated transfection (Lipofection), calcium phosphate, cationic polymers, DEAE-dextran, activated dendrimers and magnetic beads. Reagent based transfection technology market is experiencing significant growth owing to cost effectiveness and less complicated methods involved during transfection. Likewise, instrument-based method includes electroporation, biolistic technology, microinjection and laserfection.Instrument-based methods are less time consuming and accurate;these advantages drive the growth of this segment.
Browse Market Research Report:
Global Transfection Technology Market, by Geography
North America contributed the largest share, i.e.over 45%, in 2012 of the global transfection technology market. Increasing awareness about transfection applications and various government initiativesare the major factorsdriving the growth of transfection technology market in North America.For instance, in February 2012, National Cancer Institute (NCI) signed a research agreement with Polypus Transfection S.A., a France-based, privately-held company. This agreement includes Polyethylenimine (PEI) reagent from Polypus Transfection S.A that will be utilized by the National Cancer Institute for in-vitro transfection exploration to produce transfected proteins, viruses and antibodies.Europe contributed the second largest share of the total market in 2012.Utilization of nanomedicine in diagnostics, targeted drug delivery, clinical trials and drug development studies is on the peak in Europe. Transfection technologies and reagents are combined with nanoparticles for better efficacy in the above mentioned studies. For instance, the European Commission published in 2011 that it had funded around 200 projects which include utilization of nanomedicine in research and development under sixth and seventh framework program.The Asia-Pacific region is expected to witness the fastest growth (CAGR – more than 10%)due to increasing prevalence of infectious diseases and utilization of biopharmaceuticals for drug discovery and development.
Fill the form for an exclusive sample of this report: